BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29316288)

  • 1. Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non-small cell lung cancer: Meta-analysis.
    Ito M; Horita N; Nagashima A; Kaneko T
    Asia Pac J Clin Oncol; 2019 Apr; 15(2):e3-e10. PubMed ID: 29316288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Okamoto I; Nokihara H; Nomura S; Niho S; Sugawara S; Horinouchi H; Azuma K; Yoneshima Y; Murakami H; Hosomi Y; Atagi S; Ozaki T; Horiike A; Fujita Y; Okamoto H; Ando M; Yamamoto N; Ohe Y; Nakagawa K
    JAMA Oncol; 2020 May; 6(5):e196828. PubMed ID: 32163097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
    Spigel DR; Shipley DL; Waterhouse DM; Jones SF; Ward PJ; Shih KC; Hemphill B; McCleod M; Whorf RC; Page RD; Stilwill J; Mekhail T; Jacobs C; Burris HA; Hainsworth JD
    Oncologist; 2019 Dec; 24(12):e1409-e1416. PubMed ID: 31420467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
    J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
    Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
    Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
    J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.
    Pereira JR; Cheng R; Orlando M; Kim JH; Barraclough H
    Drugs R D; 2013 Dec; 13(4):289-96. PubMed ID: 24277116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
    Takeoka H; Yamada K; Naito Y; Matsuo N; Ishii H; Tokito T; Azuma K; Ichiki M; Hoshino T
    Anticancer Res; 2018 Jun; 38(6):3779-3784. PubMed ID: 29848743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study.
    Xu Y; Ma S; Ji Y; Sun X; Jiang H; Chen J; Du X; Zheng Y; Qiu G
    Lung Cancer; 2011 Jun; 72(3):327-32. PubMed ID: 21056507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
    Spigel DR; Hainsworth JD; Joseph MJ; Shipley DL; Hagan MK; Thompson DS; Burris HA; Greco FA
    Cancer; 2018 May; 124(9):1982-1991. PubMed ID: 29451696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
    Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
    Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.
    Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T
    Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
    Hainsworth JD; Waterhouse DM; Shih KC; Boccia RV; Priego VM; McCleod MJ; Kudrik FJ; Mitchell RB; Burris HA; Greco FA; Spigel DR
    Lung Cancer; 2018 Apr; 118():6-12. PubMed ID: 29572004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non-Small-cell Lung Cancer: A TRAIL Trial.
    Park CK; Oh IJ; Kim KS; Choi YD; Jang TW; Kim YS; Lee KH; Shin KC; Jung CY; Yang SH; Ryu JS; Jang SH; Yoo SS; Yong SJ; Lee KY; In KH; Lee MK; Kim YC
    Clin Lung Cancer; 2017 Jul; 18(4):e289-e296. PubMed ID: 28185792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
    Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
    PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Kuyama S; Ochi N; Bessho A; Hotta K; Ikeda G; Kishino D; Kubo T; Harada D; Fujimoto N; Nakanishi M; Umeno T; Okada T; Chikamori K; Yamagishi T; Ohashi K; Ichihara E; Takigawa N; Tanimoto M; Kiura K
    Lung Cancer; 2017 Oct; 112():188-194. PubMed ID: 29191594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.